Yorvipath denied as not medically necessary by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Yorvipath for Medical Necessity — and How to Build a Winning Appeal

A medical-necessity denial means Humana determined that the clinical information submitted did not satisfy its criteria for coverage. For Yorvipath (palopegteriparatide) — a PTH replacement therapy for chronic hypoparathyroidism — these denials most often occur when the submitted documentation does not clearly establish the diagnosis, the severity of disease, or why conventional calcium and active vitamin D therapy is insufficient. Medical-necessity denials are the most common type and also among the most successfully overturned, provided the appeal is thorough and criterion-specific.

## Why This Is Appealable

Humana's medical-necessity criteria must align with standards of medical practice. If the prescribing endocrinologist believes Yorvipath is the appropriate treatment for this patient at this time, the denial is not a final answer — it is the beginning of a structured process. Medical-necessity appeals succeed when the appeal package methodically addresses every criterion in Humana's policy with specific, dated clinical evidence. Vague or general letters rarely succeed; criterion-by-criterion mapping almost always performs better.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, you have the right to a full-and-fair internal review conducted by a qualified clinical reviewer not involved in the initial denial. Submit within the timeframe specified on the denial letter — typically 180 days.
• External review (ACA §2719): If the internal appeal is denied, escalate to an independent review organization. The IRO reviews the clinical record de novo and its determination is binding on Humana. The external review window is generally up to four months from denial.
• Expedited review: If the condition is urgent or delay would cause serious harm, request expedited review at both the internal and external level simultaneously.

## Documentation to Gather

1. Confirmed diagnosis — laboratory values establishing the hypoparathyroidism diagnosis, documented cause (surgical, autoimmune, idiopathic), and duration of the condition. 2. Symptom and severity record — chart notes documenting the frequency and severity of hypocalcemia-related symptoms (neuromuscular, cardiovascular, quality-of-life impacts) over time. 3. Prior-treatment documentation — a complete, dated record of conventional therapy attempts: agents used, duration of each, laboratory response, and reason for inadequacy (poor control, adverse effects, or inability to achieve therapeutic targets without harm). 4. Current medication list — showing all relevant medications and confirming there are no overlooked conventional alternatives Humana might cite. 5. Prescriber medical-necessity letter — the core of the appeal. Should address each of Humana's coverage criteria by name, map each criterion to specific chart evidence, explain why Yorvipath is medically necessary for this patient, and confirm that conventional alternatives are inadequate. 6. Relevant specialist notes — nephrology if renal complications are present; cardiology if cardiovascular manifestations are documented.

## Criteria-Mapping Strategy

Before writing the appeal, download Humana's published Yorvipath or hypoparathyroidism coverage policy. Create a two-column table: left column lists each coverage criterion verbatim; right column cites the exact chart document and date that satisfies it. Submit this table as a cover sheet to the appeal package. This format makes the reviewer's job straightforward and leaves no criterion unaddressed — the most common reason denials are upheld on appeal.